Semaglutide Research for Heart Failure
An evidence-based overview of research examining Semaglutide in the context of heart failure. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide has shown benefits in heart failure with preserved ejection fraction (HFpEF) in patients with obesity. The STEP-HFpEF trials demonstrated improved symptoms, physical function, and quality of life measures. In a prespecified SELECT analysis of 4,286 participants with a history of investigator-defined heart failure and established cardiovascular disease, the MACE hazard ratio was 0.72, cardiovascular death HR 0.76, and all-cause death HR 0.81 (95% CI 0.66-1.00). The analysis found no clear interaction by heart-failure phenotype; it was not a dedicated trial of treatment for reduced-ejection-fraction heart failure. Weight loss and metabolic changes are plausible contributors, but these studies do not establish which mechanism produced the observed effects.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.